North America Anti-Obesity Drugs Market

North America Anti-Obesity Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Mechanism of Action, By Route Of Administration (Oral Route and Subcutaneous Route), By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

Report Id: KBV-14790 Publication Date: April-2023 Number of Pages: 72
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Anti-Obesity Drugs Market, by Drug Type
1.4.2 North America Anti-Obesity Drugs Market, by Mechanism of Action
1.4.3 North America Anti-Obesity Drugs Market, by Route Of Administration
1.4.4 North America Anti-Obesity Drugs Market, by Distribution Channel
1.4.5 North America Anti-Obesity Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Anti-Obesity Drugs Market by Drug Type
3.1 North America Prescription Drugs Market by Country
3.2 North America Over The Counter Drugs Market by Country

Chapter 4. North America Anti-Obesity Drugs Market by Mechanism of Action
4.1 North America Centrally Acting Market by Country
4.2 North America Peripherally Acting Market by Country

Chapter 5. North America Anti-Obesity Drugs Market by Route Of Administration
5.1 North America Oral Route Market by Country
5.2 North America Subcutaneous Route Market by Country

Chapter 6. North America Anti-Obesity Drugs Market by Distribution Channel
6.1 North America Hospital Pharmacies Market by Country
6.2 North America Retail Pharmacies Market by Country
6.3 North America Online Pharmacies Market by Country

Chapter 7. North America Anti-Obesity Drugs Market by Country
7.1 US Anti-Obesity Drugs Market
7.1.1 US Anti-Obesity Drugs Market by Drug Type
7.1.2 US Anti-Obesity Drugs Market by Mechanism of Action
7.1.3 US Anti-Obesity Drugs Market by Route Of Administration
7.1.4 US Anti-Obesity Drugs Market by Distribution Channel
7.2 Canada Anti-Obesity Drugs Market
7.2.1 Canada Anti-Obesity Drugs Market by Drug Type
7.2.2 Canada Anti-Obesity Drugs Market by Mechanism of Action
7.2.3 Canada Anti-Obesity Drugs Market by Route Of Administration
7.2.4 Canada Anti-Obesity Drugs Market by Distribution Channel
7.3 Mexico Anti-Obesity Drugs Market
7.3.1 Mexico Anti-Obesity Drugs Market by Drug Type
7.3.2 Mexico Anti-Obesity Drugs Market by Mechanism of Action
7.3.3 Mexico Anti-Obesity Drugs Market by Route Of Administration
7.3.4 Mexico Anti-Obesity Drugs Market by Distribution Channel
7.4 Rest of North America Anti-Obesity Drugs Market
7.4.1 Rest of North America Anti-Obesity Drugs Market by Drug Type
7.4.2 Rest of North America Anti-Obesity Drugs Market by Mechanism of Action
7.4.3 Rest of North America Anti-Obesity Drugs Market by Route Of Administration
7.4.4 Rest of North America Anti-Obesity Drugs Market by Distribution Channel

Chapter 8. Company Profiles
8.1 Pfizer, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional & Segmental Analysis
8.1.4 Research & Development Expense
8.2 Boehringer Ingelheim International Gmbh
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 GlaxoSmithKline PLC (GSK)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 Novo Nordisk A/S
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental & Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 Rhythm Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.6 Gelesis Holdings Inc (PureTech Health)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.6.4.2 Approvals and Trials:
8.7 Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Acquisition and Mergers:
8.8 Vivus LLC
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Approvals and Trials:
8.9 CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
8.9.1 Company Overview
8.10. KVK Tech, Inc.
8.10.1 Company Overview
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo